A Clinical Trial to Investigate the Efficacy and Safety of Evogliptin

Sponsor
Dong-A ST Co., Ltd.
Study ID
NCT02946541
Phase
PHASE3
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This is a randomized, double-blind, placebo-controlled, phase III clinical trial to investigate the efficacy and safety of evogliptin after oral administration in patients with type 2 diabetes who have inadequate glycemic control on diet and exercise.

Key Dates

First listed
Oct 27, 2016
Start date
Jul 31, 2013
Status verified
Mar 2017
Primary completion
Oct 31, 2014
Completion
Apr 30, 2015

Study Design

Enrollment
160 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: evogliptin 5mg
    evogliptin 5mg QD
  • Placebo Comparator: placebo
    Placebo QD

Primary Outcome Measure

HbA1c [ Time Frame: Change from baseline at 24 weeks ]

Related Studies